Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.54 |
| ▸ | JAK3 | P52333 | 19/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 16/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239700 | 0.93 | JAK2 (0.53) | JAK2JAK3PTK2 | |
| SCHEMBL18239702 | 0.91 | JAK2 (0.55) | JAK2JAK3PTK2 | |
| SCHEMBL18239815 | 0.91 | JAK2 (0.60) | JAK2JAK3PTK2 | |
| SCHEMBL3219894 | 0.88 | JAK2 (0.68) | JAK2JAK3PTK2 | |
| SCHEMBL3219158 | 0.86 | JAK2 (0.54) | JAK2JAK3PTK2 | |
| SCHEMBL15462880 | 0.85 | JAK2 (0.57) | JAK2JAK3PTK2 | |
| SCHEMBL3209843 | 0.82 | JAK2 (0.57) | JAK2JAK3PTK2 | |
| SCHEMBL15459838 | 0.81 | JAK2 (0.57) | JAK2JAK3PTK2 | |
| SCHEMBL3212704 | 0.81 | JAK2 (0.67) | JAK2JAK3PTK2 | |
| SCHEMBL3226670 | 0.79 | JAK2 (0.52) | JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK3 3/4885PTK2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.